Several cases of deep venous thrombosis in people who had recently received Vaxzevria (previously known as COVID-19 Vaccine AstraZeneca) have recently been reported, mainly presenting as cerebral vein/cerebral venous sinus thrombosis. This syndrome has been termed “vaccine-induced immune thrombotic thrombocytopenia (VITT)”. Acute spleno-porto-mesenteric vein thrombosis is an uncommon but serious condition with potential sequelae, such as small-bowel gangrene and end-stage liver failure. We describe a case of concomitant thrombosis of portal, superior mesenteric and splenic veins in a young female patient with no other risk factors who received Vaxzevria (previously ChAdOx1 nCoV-19 vaccine, AstraZeneca) 17 days before. The diagnostic workup and the successful endovascular treatment and systemic anticoagulation management is reported.
Successful treatment of acute spleno-porto-mesenteric vein thrombosis after ChAdOx1 nCoV-19 vaccine : a case report / M. Umbrello, N. Brena, R. Vercelli, R.A. Foa, M. Femia, U. Rossi, G.M. Podda, F. Cortellaro, S. Muttini. - In: JOURNAL OF CRITICAL CARE. - ISSN 0883-9441. - 65(2021), pp. 72-75. [10.1016/j.jcrc.2021.05.021]
Successful treatment of acute spleno-porto-mesenteric vein thrombosis after ChAdOx1 nCoV-19 vaccine : a case report
M. Umbrello
;N. Brena;R. Vercelli;G.M. Podda;
2021
Abstract
Several cases of deep venous thrombosis in people who had recently received Vaxzevria (previously known as COVID-19 Vaccine AstraZeneca) have recently been reported, mainly presenting as cerebral vein/cerebral venous sinus thrombosis. This syndrome has been termed “vaccine-induced immune thrombotic thrombocytopenia (VITT)”. Acute spleno-porto-mesenteric vein thrombosis is an uncommon but serious condition with potential sequelae, such as small-bowel gangrene and end-stage liver failure. We describe a case of concomitant thrombosis of portal, superior mesenteric and splenic veins in a young female patient with no other risk factors who received Vaxzevria (previously ChAdOx1 nCoV-19 vaccine, AstraZeneca) 17 days before. The diagnostic workup and the successful endovascular treatment and systemic anticoagulation management is reported.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S088394412100109X-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
853.41 kB
Formato
Adobe PDF
|
853.41 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.